Active Ingredient History
Pyrimethamine, sold under the trade name Daraprim, is one of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. In addition it was approved in Chemoprophylaxis of Malaria. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a prophylactic agent for travelers to most areas. Pyrimethamine is well absorbed with peak levels occurring between 2 to 6 hours following administration. It is eliminated slowly and has a plasma half-life of approximately 96 hours. Pyrimethamine is 87% bound to human plasma proteins. Pyrimethamine acts by selectively inhibiting malarial dihydrofolate reductase-thymidylate synthase and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and Toxoplasma gondii. Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans. The action of pyrimethamine against Toxoplasma gondii is greatly enhanced when used in conjunction with sulfonamides. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)
Anemia (Phase 4)
Anemia, Sickle Cell (Phase 3)
Autoimmune Diseases (Phase 1)
Cardiotoxicity (Phase 2)
Child Mortality (Phase 3)
Chorioretinitis (Phase 3)
Depression (Phase 3)
Encephalitis (Phase 4)
Gangliosidoses, GM2 (Phase 1/Phase 2)
G(M2) Ganglioside (Phase 1)
Head and Neck Neoplasms (Early Phase 1)
Healthy Volunteers (Phase 3)
HIV (Phase 4)
HIV Infections (Phase 4)
Infant, Premature, Diseases (Phase 4)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Lymphatic Diseases (Phase 1)
Lymphoproliferative Disorders (Phase 1)
Malaria ()
Malaria, Falciparum (Phase 4)
Malaria, Vivax (Phase 3)
Myelodysplastic Syndromes (Phase 1)
Only Child (Phase 3)
Parasitemia (Phase 3)
Parasitic Diseases (Phase 3)
Perinatal Death (Phase 4)
Pharmacokinetics (Phase 4)
Plasmodium (Phase 4)
Plasmodium falciparum (Phase 3)
Pneumonia, Pneumocystis (Phase 3)
Pregnancy (Phase 4)
Pregnancy Complications (Phase 4)
Premature Birth (Phase 3)
Respiratory Tract Infections (Phase 3)
Sandhoff Disease (Phase 1/Phase 2)
Schistosoma haematobium (Phase 2/Phase 3)
Schistosoma mansoni (Phase 3)
Schistosomiasis haematobia (Phase 2)
Schizophrenia (Phase 3)
Sexually Transmitted Diseases (Phase 3)
Stillbirth (Phase 4)
Tay-Sachs Disease (Phase 1/Phase 2)
Therapeutic Equivalency (Phase 1)
Toxoplasmosis (Phase 4)
Toxoplasmosis, Cerebral (Phase 2)
Toxoplasmosis, Congenital (Phase 3)
Treatment Adherence and Compliance (Phase 4)
Treatment Outcome (Phase 4)
Trichomonas Vaginitis (Phase 3)
Vaginosis, Bacterial (Phase 3)
Wound Infection (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
